TrialsgrambetaRCTs are beautiful

VALOR-HCM

2022

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

In 112 patients with obstructive HCM referred for septal reduction therapy, mavacamten reduced the need to proceed with or remain eligible for septal reduction therapy compared with placebo.

Result

Composite at week 16: decision to proceed with septal reduction therapy, or remaining SRT-eligible
Absolute difference
58.9 points
NNT
2
Effect estimate

difference58.995% CI 44.0-73.9 · P < 0.001

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
myosin inhibitor
Design
Double-blind placebo-controlled RCT, phase 3
Relevance
Supporting: context rather than must-know.
Source
Desai MY, et al. J Am Coll Cardiol. 2022;80(2):95-108.doi 10.1016/j.jacc.2022.04.048

Discussion & critique

Small, short-term surrogate endpoint (SRT eligibility/referral rather than actual procedures or hard outcomes). Demonstrated that mavacamten can defer or avoid invasive septal reduction in obstructive HCM.

Discussed in podcasts